« Return to News | Drug Sponsors

Athera Biotechnologies awarded collaborative research grant

Monday, June 17, 2013 01:45 PM

Athera Biotechnologies said future development costs of its fully human antibody PC-mAb, until proof-of-concept, will be co-funded by the European Union’s Seventh Framework Program for Research (FP7) through a collaborative research grant.

PC-mAb targets phosphorylcholine and is being developed for treatment of patients with an increased risk of atherosclerosis-related cardiovascular events and death. This includes myocardial infarction patients and patients with peripheral arterial disease undergoing vein graft surgery.

“The grant underpins the level of innovation of the PC-mAb project and will substantially contribute to the pace of future development,” said Torbjörn Bjerke, chief executive officer of Karolinska Development, which owns 65% of Athera Biotechnologies.

The $8 million grant has been provided to the CARDIMMUN consortium, consisting of Athera, Leiden University Medical Center (LUMC), Turku PET Center (Turku University), Clinical Trial Consultants (CTC) and Smerud Medical Research. The project has a total budget of nearly $10.7 million and will run for three years, focusing on preclinical activities and clinical trials aimed at demonstrating proof-of-concept. LUMC is the project coordinator and will lead the project with Athera.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.